Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does POLATUZUMAB VEDOTIN Cause Urinary retention? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Urinary retention have been filed in association with POLATUZUMAB VEDOTIN (POLIVY). This represents 0.2% of all adverse event reports for POLATUZUMAB VEDOTIN.

7
Reports of Urinary retention with POLATUZUMAB VEDOTIN
0.2%
of all POLATUZUMAB VEDOTIN reports
0
Deaths
5
Hospitalizations

How Dangerous Is Urinary retention From POLATUZUMAB VEDOTIN?

Of the 7 reports, 5 (71.4%) required hospitalization, and 4 (57.1%) were considered life-threatening.

Is Urinary retention Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for POLATUZUMAB VEDOTIN. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does POLATUZUMAB VEDOTIN Cause?

Disease progression (1,131) Off label use (692) Anaemia (344) Blood lactate dehydrogenase increased (307) Drug ineffective (305) Neutropenia (303) Death (295) Covid-19 (286) Febrile neutropenia (286) Pyrexia (285)

What Other Drugs Cause Urinary retention?

MIRABEGRON (706) QUETIAPINE (617) TAMSULOSIN (475) ADALIMUMAB (452) MORPHINE (407) OLANZAPINE (405) SERTRALINE (380) PREGABALIN (376) RISPERIDONE (375) DULOXETINE (362)

Which POLATUZUMAB VEDOTIN Alternatives Have Lower Urinary retention Risk?

POLATUZUMAB VEDOTIN vs POLATUZUMAB VEDOTIN-PIIQ POLATUZUMAB VEDOTIN vs POLIDOCANOL POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350 POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350\POTASSIUM\SODIUM BICARBONATE\SODIUM

Related Pages

POLATUZUMAB VEDOTIN Full Profile All Urinary retention Reports All Drugs Causing Urinary retention POLATUZUMAB VEDOTIN Demographics